Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 865-872

  Boschetti, Gilles ^a,b   Laidet, Marc'Harid ^a   Moussata, Driffa ^a   Stefanescu, Carmen ^c   Roblin, Xavier ^d   Phelip, Gildas ^a   Cotte, Eddy ^a   Passot, Guillaume ^a   Francois, Yves ^a   Drai, Jocelyne ^a   Del Tedesco, Emilie ^d   Bouhnik, Yoram ^c   Flourie, Bernard ^a,b   Nancey, Stephane ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; FECAL CALPROTECTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; ASYMPTOMATIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOSCOPIC SURGERY; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; ILEOCOLONOSCOPY; INTESTINE ENDOSCOPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; RUTGEERTS SCORE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ADOLESCENT; CHEMISTRY; COLON RESECTION; FECES; GASTROINTESTINAL ENDOSCOPY; ILEUM; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASYMPTOMATIC DISEASES; C-REACTIVE PROTEIN; COHORT STUDIES; COLECTOMY; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; ILEUM; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930762906     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.30     Document Type: Article

References (28)

1. Bernell O, Lapidus A, Hellers G et al. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 2000;87: 1697-701.
2. Buisson A, Chevaux JB, Allen PB et al. The natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012;35: 625-33.
3. Van Assche G, Dignass A, Reinisch W et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4: 63-101.
4. Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99: 956-63.
5. Kopylov U, Rosenfeld G, Bressler B et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Infl amm Bowel Dis 2014;20: 742-56.
6. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140: 1817-26.
7. Poullis A, Foster R, Mendall M et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18: 756-62.
8. Sipponen T, Savilahti E, Kolho KL et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14: 40-6.
9. D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 2218-24.
10. Nancey S, Boschetti G, Moussata D et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19: 1043-52.
11. Orlando A, Modesto I, Castiglione F et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006;10: 17-22.
12. Scarpa M, D'Inca R, Basso D et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 2007;50: 861-9.
13. Lamb CA, Mohiuddin MK, Gicquel J et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009;96: 663-74.
14. Sorrentino D, Paviotti A, Terrosu G et al. Low-dose maintenance therapy with infl iximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010;8: 591-9.
15. Yamamoto T, Shiraki M, Bamba T et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileo-colonic resection: a prospective pilot study. United European Gastroenterol J 2013;1: 368-74.
16. Herranz MT, Ruiz-Zorrilla R, Alcaide N et al. Is faecal calprotectin a useful marker of postoperative recurrence in Crohn's ileal disease? J Crohns Colitis 2012;6: S63.
17. Lasson A, Strid H, Hman L, et al. Fecal calprotectin one year after ileocaecal resection for crohn's disease-a comparison with findings at ileocolonoscopy. J Crohns Colitis 2013;8: 789-95.
18. Kamm MA, De Cruz PP, Wright EK et al. Optimising post-operative Crohn's disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J Crohns Colitis 2014;Sup1: S13.
19. Boisrivant M, Leoni M, Taricotti D et al. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988;10: 401-5.
20. Regueiro M, Kip KE, Schraut W et al. Crohn's disease activity index does not correlate wiThendoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011;17: 118-26.
21. Jones J, Loftus EV, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6: 1218-24.
22. Lobaton T, Lopez-Garcia A, Rodrguez-Moranta F et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013;7: 641-51.
23. Primas C, Fruhwald G, Angelberger S et al. Role of fecal calprotectin in predicting ilecolonic endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2013;144: S619-S620.
24. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105: 162-9.
25. Rutgeerts P, Geboes K, Vantrappen G et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25: 665-72.
26. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010;16: 1091-2.
27. Naismith GD, Smith LA, Barry SJE et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013;37: 613-21.
28. De Vos M, Louis EJ, Jahnsen J et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infl iximab maintenance therapy. Inflamm Bowel Dis 2013;19: 2111-7.